Holding(s) in Company

Mar 25, 2010

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

HomeRNS NewsHolding in CompanyHolding(s) in Company
RNS Number : 2045J
Advanced Medical Solutions Grp PLC
25 March 2010
 



 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

  ADVANCED MEDICAL SOLUTIONS GRO

 

2 Reason for the notification (please tick the appropriate box or boxes):

 

An acquisition or disposal of voting rights

X

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


 

An event changing the breakdown of voting rights


 

Other (please specify):

 


 

3. Full name of person(s) subject to the notification obligation:

 

AXA S.A.

4. Full name of shareholder(s) (if different from 3.):

 


5. Date of the transaction and date on which the threshold is crossed or reached:

 

24/03/2010

6. Date on which issuer notified:

 

25/03/2010

7. Threshold(s) that is/are crossed or reached:

 

11%

 

8. Notified details:

A: Voting rights attached to shares

 

Class/type of

shares


if possible using

the ISIN CODE

Situation previous

to the triggering

transaction

Resulting situation after the triggering transaction

Number

of

Shares

Number

of

Voting

Rights

Number

of shares

Number of voting

rights

% of  voting rights

Direct

Direct

Indirect

Direct

Indirect


16,341,554

16,341,554

400,000

400,000

16,016,554

0.28

11.04

453659

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financial

instrument

Expiration

date

Exercise/

Conversion

Period

Number of voting

rights that may be

acquired if the

instrument is

exercised/ converted.

 

% of voting

rights






 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financial

instrument

Exercise

price

Expiration

date

Exercise/

Conversion

period

Number of voting

rights instrument

refers to

% of voting rights

 






Nominal

Delta

 



 

Total (A+B+C)

 

Number of voting rights

Percentage of voting rights

16,416,554

11.32%

 

9. Chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held, if applicable:

 

 

Name of the Company/Fund
Number of Shares
% of issued share capital
AXA IM UK
400,000.00
0.275831
Direct
 
 
AXA IM UK
16,016,554.00
11.044653
Indirect
 
 
Total Direct
400,000
0.27583
Total Indirect
16,016,554
11.04465
TOTAL
16,416,554
11.32048

 

Proxy Voting:

 

10. Name of the proxy holder:

 


11. Number of voting rights proxy holder will cease to hold:

 


12. Date on which proxy holder will cease to hold voting rights:

 


 

13. Additional information:

 


14. Contact name:

 

KYERE TABIRI

15. Contact telephone number:

 

020 7003 1510

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

HOLUVVSRRVAOUAR

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.